Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-05-28

AUTHORS

Xiaoling Cai, Linong Ji

ABSTRACT

IntroductionThis study aimed to investigate the generalizability of the results of cardiovascular outcome trials (CVOTs) of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) to Chinese patients with type 2 diabetes mellitus (T2DM).MethodsThe 3B (Blood Glucose, Blood Pressure, and Blood Lipid) population, a nationally representative population of patients with T2DM in China (n = 25,411), was examined for eligibility of enrollment in four GLP-1 RAs CVOTs (Dulaglutide-REWIND, Exenatide-EXSCEL, Liraglutide-LEADER, and Semaglutide-SUSTAIN-6). We first estimated the proportion of 3B population who would meet the six inclusion and exclusion (I/E) criteria, namely age, hemoglobin A1c (HbA1c), body mass index (BMI), estimated glomerular filtration rate (eGFR), history of cardiovascular disease (CVD), and antidiabetic medication, in each CVOT. Then we compared 11 baseline characteristics, namely age, gender, duration of diabetes, HbA1c, BMI, eGFR, history of CVD, prior myocardial infarction (MI), low-density lipoprotein cholesterol (LDL-c), diastolic blood pressure (DBP), and systolic blood pressure, between the population in each CVOT and the 3B population. Lastly, we estimated the proportion of 3B population that matched the characteristics in each CVOT population.ResultsOn the basis of the I/E criteria, 31.1% of the 3B population would have been eligible for enrollment in REWIND, 15.0% for SUSTAIN-6, 12.9% for LEADER, and 11.3% for EXSCEL. On the basis of the baseline characteristics, REWIND most closely matched the 3B population on gender, duration of diabetes, HbA1c, DBP, LDL-c, history of CVD, and prior MI. The proportion of 3B population matching on at least eight or at least ten baseline characteristics with CVOT populations was highest for REWIND compared to other CVOTs.ConclusionAmong the four GLP-1 RA CVOTs, the REWIND trial using once-weekly dulaglutide is most generalizable to Chinese patients with T2DM.Trial RegistrationTrial registration: NCT01128205 (www.clinicaltrials.gov). More... »

PAGES

1861-1870

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-021-01079-x

DOI

http://dx.doi.org/10.1007/s13300-021-01079-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1138437570

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/34047959


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, 100044, Beijing, China", 
          "id": "http://www.grid.ac/institutes/grid.411634.5", 
          "name": [
            "Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, 100044, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cai", 
        "givenName": "Xiaoling", 
        "id": "sg:person.01070217144.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070217144.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, 100044, Beijing, China", 
          "id": "http://www.grid.ac/institutes/grid.411634.5", 
          "name": [
            "Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, 100044, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ji", 
        "givenName": "Linong", 
        "id": "sg:person.07521246722.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07521246722.04"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1602/neurorx.1.3.363", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024798661", 
          "https://doi.org/10.1602/neurorx.1.3.363"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12933-018-0728-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104481176", 
          "https://doi.org/10.1186/s12933-018-0728-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00592-017-0981-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084022806", 
          "https://doi.org/10.1007/s00592-017-0981-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-05-28", 
    "datePublishedReg": "2021-05-28", 
    "description": "IntroductionThis study aimed to investigate the generalizability of the results of cardiovascular outcome trials (CVOTs) of glucagon-like peptide\u00a01 receptor agonists (GLP-1\u00a0RAs) to Chinese patients with type\u00a02 diabetes mellitus (T2DM).MethodsThe 3B (Blood Glucose, Blood Pressure, and Blood Lipid) population, a nationally representative population of patients with T2DM in China (n\u2009=\u200925,411), was examined for eligibility of enrollment in four GLP-1\u00a0RAs CVOTs (Dulaglutide-REWIND, Exenatide-EXSCEL, Liraglutide-LEADER, and Semaglutide-SUSTAIN-6). We first estimated the proportion of 3B population who would meet the six inclusion and exclusion (I/E) criteria, namely age, hemoglobin A1c (HbA1c), body mass index (BMI), estimated glomerular filtration rate (eGFR), history of cardiovascular disease (CVD), and antidiabetic medication, in each CVOT. Then we compared 11 baseline characteristics, namely age, gender, duration of diabetes, HbA1c, BMI, eGFR, history of CVD, prior myocardial infarction (MI), low-density lipoprotein cholesterol (LDL-c), diastolic blood pressure (DBP), and systolic blood pressure, between the population in each CVOT and the 3B population. Lastly, we estimated the proportion of 3B population that matched the characteristics in each CVOT population.ResultsOn the basis of the I/E criteria, 31.1% of the 3B population would have been eligible for enrollment in REWIND, 15.0% for SUSTAIN-6, 12.9% for LEADER, and 11.3% for EXSCEL. On the basis of the baseline characteristics, REWIND most closely matched the 3B population on gender, duration of diabetes, HbA1c, DBP, LDL-c, history of CVD, and prior MI. The proportion of 3B population matching on at least eight or at least ten baseline characteristics with CVOT populations was highest for REWIND compared to other CVOTs.ConclusionAmong the four GLP-1\u00a0RA CVOTs, the REWIND trial using once-weekly dulaglutide is most generalizable to Chinese patients with T2DM.Trial RegistrationTrial registration: NCT01128205 (www.clinicaltrials.gov).", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-021-01079-x", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "cardiovascular outcome trials", 
      "diastolic blood pressure", 
      "body mass index", 
      "history of CVD", 
      "duration of diabetes", 
      "prior myocardial infarction", 
      "cardiovascular disease", 
      "baseline characteristics", 
      "Chinese patients", 
      "myocardial infarction", 
      "outcome trials", 
      "blood pressure", 
      "receptor agonist", 
      "GLP-1", 
      "glucagon-like peptide-1 receptor agonists", 
      "peptide-1 receptor agonists", 
      "low-density lipoprotein cholesterol", 
      "glomerular filtration rate", 
      "systolic blood pressure", 
      "glucagon-like peptide", 
      "SUSTAIN 6", 
      "REWIND trial", 
      "weekly dulaglutide", 
      "antidiabetic medications", 
      "lipoprotein cholesterol", 
      "diabetes mellitus", 
      "mass index", 
      "filtration rate", 
      "IntroductionThis study", 
      "exclusion criteria", 
      "type 2", 
      "patients", 
      "representative population", 
      "trials", 
      "HbA1c", 
      "mellitus", 
      "T2DM", 
      "diabetes", 
      "agonists", 
      "age", 
      "enrollment", 
      "population", 
      "duration", 
      "proportion", 
      "EXSCEL", 
      "dulaglutide", 
      "gender", 
      "medications", 
      "infarction", 
      "LDL", 
      "EGFR", 
      "disease", 
      "cholesterol", 
      "history", 
      "ConclusionAmong", 
      "hemoglobin", 
      "ResultsOn", 
      "eligibility", 
      "criteria", 
      "generalizability", 
      "pressure", 
      "peptides", 
      "index", 
      "study", 
      "characteristics", 
      "rate", 
      "results", 
      "inclusion", 
      "basis", 
      "types", 
      "rewind", 
      "E-criterion", 
      "China", 
      "leaders"
    ], 
    "name": "Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus", 
    "pagination": "1861-1870", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1138437570"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-021-01079-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "34047959"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-021-01079-x", 
      "https://app.dimensions.ai/details/publication/pub.1138437570"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:48", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_891.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-021-01079-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01079-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01079-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01079-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01079-x'


 

This table displays all metadata directly associated to this object as RDF triples.

158 TRIPLES      21 PREDICATES      103 URIs      91 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-021-01079-x schema:about anzsrc-for:11
2 anzsrc-for:1102
3 anzsrc-for:1103
4 schema:author N4ced21d9f42e46719bf9c83c4461a7e1
5 schema:citation sg:pub.10.1007/s00592-017-0981-2
6 sg:pub.10.1186/s12933-018-0728-6
7 sg:pub.10.1602/neurorx.1.3.363
8 schema:datePublished 2021-05-28
9 schema:datePublishedReg 2021-05-28
10 schema:description IntroductionThis study aimed to investigate the generalizability of the results of cardiovascular outcome trials (CVOTs) of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) to Chinese patients with type 2 diabetes mellitus (T2DM).MethodsThe 3B (Blood Glucose, Blood Pressure, and Blood Lipid) population, a nationally representative population of patients with T2DM in China (n = 25,411), was examined for eligibility of enrollment in four GLP-1 RAs CVOTs (Dulaglutide-REWIND, Exenatide-EXSCEL, Liraglutide-LEADER, and Semaglutide-SUSTAIN-6). We first estimated the proportion of 3B population who would meet the six inclusion and exclusion (I/E) criteria, namely age, hemoglobin A1c (HbA1c), body mass index (BMI), estimated glomerular filtration rate (eGFR), history of cardiovascular disease (CVD), and antidiabetic medication, in each CVOT. Then we compared 11 baseline characteristics, namely age, gender, duration of diabetes, HbA1c, BMI, eGFR, history of CVD, prior myocardial infarction (MI), low-density lipoprotein cholesterol (LDL-c), diastolic blood pressure (DBP), and systolic blood pressure, between the population in each CVOT and the 3B population. Lastly, we estimated the proportion of 3B population that matched the characteristics in each CVOT population.ResultsOn the basis of the I/E criteria, 31.1% of the 3B population would have been eligible for enrollment in REWIND, 15.0% for SUSTAIN-6, 12.9% for LEADER, and 11.3% for EXSCEL. On the basis of the baseline characteristics, REWIND most closely matched the 3B population on gender, duration of diabetes, HbA1c, DBP, LDL-c, history of CVD, and prior MI. The proportion of 3B population matching on at least eight or at least ten baseline characteristics with CVOT populations was highest for REWIND compared to other CVOTs.ConclusionAmong the four GLP-1 RA CVOTs, the REWIND trial using once-weekly dulaglutide is most generalizable to Chinese patients with T2DM.Trial RegistrationTrial registration: NCT01128205 (www.clinicaltrials.gov).
11 schema:genre article
12 schema:isAccessibleForFree true
13 schema:isPartOf N779438c4728b43c8811865362e16baa9
14 N8f3bb88f849a493da997d8723d2fa6ed
15 sg:journal.1044057
16 schema:keywords China
17 Chinese patients
18 ConclusionAmong
19 E-criterion
20 EGFR
21 EXSCEL
22 GLP-1
23 HbA1c
24 IntroductionThis study
25 LDL
26 REWIND trial
27 ResultsOn
28 SUSTAIN 6
29 T2DM
30 age
31 agonists
32 antidiabetic medications
33 baseline characteristics
34 basis
35 blood pressure
36 body mass index
37 cardiovascular disease
38 cardiovascular outcome trials
39 characteristics
40 cholesterol
41 criteria
42 diabetes
43 diabetes mellitus
44 diastolic blood pressure
45 disease
46 dulaglutide
47 duration
48 duration of diabetes
49 eligibility
50 enrollment
51 exclusion criteria
52 filtration rate
53 gender
54 generalizability
55 glomerular filtration rate
56 glucagon-like peptide
57 glucagon-like peptide-1 receptor agonists
58 hemoglobin
59 history
60 history of CVD
61 inclusion
62 index
63 infarction
64 leaders
65 lipoprotein cholesterol
66 low-density lipoprotein cholesterol
67 mass index
68 medications
69 mellitus
70 myocardial infarction
71 outcome trials
72 patients
73 peptide-1 receptor agonists
74 peptides
75 population
76 pressure
77 prior myocardial infarction
78 proportion
79 rate
80 receptor agonist
81 representative population
82 results
83 rewind
84 study
85 systolic blood pressure
86 trials
87 type 2
88 types
89 weekly dulaglutide
90 schema:name Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus
91 schema:pagination 1861-1870
92 schema:productId N123c3d84862c4287a4d73607e0184478
93 N65a6bddb365a446da0bd12865e4b3b2d
94 Ncc7f1828928e4702873d53e8b199bff4
95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1138437570
96 https://doi.org/10.1007/s13300-021-01079-x
97 schema:sdDatePublished 2022-10-01T06:48
98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
99 schema:sdPublisher N372bf306cb7a4a4d900222513bd9f58a
100 schema:url https://doi.org/10.1007/s13300-021-01079-x
101 sgo:license sg:explorer/license/
102 sgo:sdDataset articles
103 rdf:type schema:ScholarlyArticle
104 N123c3d84862c4287a4d73607e0184478 schema:name dimensions_id
105 schema:value pub.1138437570
106 rdf:type schema:PropertyValue
107 N372bf306cb7a4a4d900222513bd9f58a schema:name Springer Nature - SN SciGraph project
108 rdf:type schema:Organization
109 N4ced21d9f42e46719bf9c83c4461a7e1 rdf:first sg:person.01070217144.87
110 rdf:rest N97f4d053fdbd4e6b83be9a40ca994d04
111 N65a6bddb365a446da0bd12865e4b3b2d schema:name doi
112 schema:value 10.1007/s13300-021-01079-x
113 rdf:type schema:PropertyValue
114 N779438c4728b43c8811865362e16baa9 schema:volumeNumber 12
115 rdf:type schema:PublicationVolume
116 N8f3bb88f849a493da997d8723d2fa6ed schema:issueNumber 7
117 rdf:type schema:PublicationIssue
118 N97f4d053fdbd4e6b83be9a40ca994d04 rdf:first sg:person.07521246722.04
119 rdf:rest rdf:nil
120 Ncc7f1828928e4702873d53e8b199bff4 schema:name pubmed_id
121 schema:value 34047959
122 rdf:type schema:PropertyValue
123 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
124 schema:name Medical and Health Sciences
125 rdf:type schema:DefinedTerm
126 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
127 schema:name Cardiorespiratory Medicine and Haematology
128 rdf:type schema:DefinedTerm
129 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
130 schema:name Clinical Sciences
131 rdf:type schema:DefinedTerm
132 sg:journal.1044057 schema:issn 1869-6953
133 1869-6961
134 schema:name Diabetes Therapy
135 schema:publisher Springer Nature
136 rdf:type schema:Periodical
137 sg:person.01070217144.87 schema:affiliation grid-institutes:grid.411634.5
138 schema:familyName Cai
139 schema:givenName Xiaoling
140 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070217144.87
141 rdf:type schema:Person
142 sg:person.07521246722.04 schema:affiliation grid-institutes:grid.411634.5
143 schema:familyName Ji
144 schema:givenName Linong
145 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07521246722.04
146 rdf:type schema:Person
147 sg:pub.10.1007/s00592-017-0981-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084022806
148 https://doi.org/10.1007/s00592-017-0981-2
149 rdf:type schema:CreativeWork
150 sg:pub.10.1186/s12933-018-0728-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104481176
151 https://doi.org/10.1186/s12933-018-0728-6
152 rdf:type schema:CreativeWork
153 sg:pub.10.1602/neurorx.1.3.363 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024798661
154 https://doi.org/10.1602/neurorx.1.3.363
155 rdf:type schema:CreativeWork
156 grid-institutes:grid.411634.5 schema:alternateName Department of Endocrinology and Metabolism, Peking University People’s Hospital, 100044, Beijing, China
157 schema:name Department of Endocrinology and Metabolism, Peking University People’s Hospital, 100044, Beijing, China
158 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...